Wong VW, Wong GL, Chan AW, Chu WC, Choi PC, Chim AM, et al. Treatment of non-alcoholic steatohepatitis with Phyllanthus urinaria: A randomized trial. J Gastroenterol Hepatol. 2013;28(1):57-62.Vincent Wai-Sun, WongGrace Lai-Hung, WongAnthony Wing-Hung, ChanWinnie Chiu-Wing, ...
Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations, starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis (NASH), cirrhosis or even hepatocellular carcinoma. NAFLD is a major health burden, and its incidence is increasing worldwide...
Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. Non-alcoholic fatty liver disease (NAFLD) refers to a disease spectrum, ranging from mere hepatic steatosis to hepatic necroinflammation (NASH, non-alcohol... D Schuppan,JM Schattenberg - 《Journal of Gastroenterology & Hepato...
Objective To investigate the effect of puerarin on hepatic lipid of nonalcoholic fatty Liver disease(NAFLD)rats. 目的观察葛根素对非酒精性脂肪肝大鼠模型肝脏脂质的影响。 5) nonalcoholic fatty liver 非酒精性脂肪肝 1. Experiment study onnonalcoholic fatty livermodel induced by injection of oxytetracyclin...
(or therapeutically effective) variant or functional fragment of SEQUENCE ID NO: 1 (hereafter "peptide active agent" or "peptide of the invention"), in a method for the treatment or prevention of non-alcoholic fatty liver disease (NAFLD), in particular non-alcoholic steatohepatitis (NASH), in...
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH). Expert Opin Investig Drugs. 2020;29:623–32. Article CAS PubMed Google Scholar Sun L, Pang Y, Wang X, Wu Q, Liu H, Liu B, et al. Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and ...
Fatty liver disease (FLD) means you have extra fat in your liver. You might hear your doctor call it hepatic steatosis. Most of the time, it doesn't cause symptoms, but over time a buildup of fat makes it harder for your liver to work. ...
Nonalcoholic steatohepatitis (NASH), unlike simple steatosis, is a potentially progressive disease. Various types of drugs have been explored for the treatment of NASH. We reviewed the various therapies available, with particular emphasis on their efficacy for the improvement of hepatic fibrosis. Treat...
Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver condition that affects a quarter of the global adult population. To date, only a few NAFLD risk prediction models have been developed for Chinese older adults aged ≥ 60 years. Thi
Nonalcoholic fatty liver disease (NAFLD) has become the world's largest chronic liver disease, while there is still no specific drug to treat NAFLD. Traditional Chinese Medicine (TCM) have been widely used in hepatic diseases for centuries in Asia, and T